scholarly journals A Thyroid-stimulating Hormone (TSH) Producing Adenoma in a Patient with Severe Hypothyroidism: Thyroxine Replacement Reduced the TSH Level and Tumor Size

2020 ◽  
Vol 7 (1) ◽  
pp. 17-21
Author(s):  
Hiroshi Arimura ◽  
Rofat Askoro ◽  
Shingo Fujio ◽  
Fauziah C. Ummah ◽  
Tomoko Takajo ◽  
...  
Keyword(s):  
Tumor Size ◽  
Thyroid Stimulating Hormone ◽  
Thyroxine Replacement ◽  
Stimulating Hormone

scholarly journals Immediate postoperative measurement of thyroid-stimulating hormone as an early predictor of remission in thyroid-stimulating hormone–secreting pituitary adenomas

2020 ◽  
pp. 1-7
Author(s):  
Soo Heon Kim ◽  
Cheol Ryong Ku ◽  
Minkyun Na ◽  
Jihwan Yoo ◽  
Woohyun Kim ◽  
...  
Keyword(s):  
Pituitary Adenoma ◽  
Tumor Size ◽  
Thyroid Stimulating Hormone ◽  
Early Postoperative Period ◽  
En Bloc ◽  
Rare Type ◽  
Csf Rhinorrhea ◽  
Extracapsular Dissection ◽  
Stimulating Hormone

OBJECTIVEThyroid-stimulating hormone (TSH)–secreting pituitary adenoma (TSHoma) is a rare type of pituitary adenoma; thus, little is known about TSHomas. The purpose of this study was to analyze clinical characteristics and therapeutic outcomes of TSHomas based on a single-center experience. The authors also searched for reliable preoperative and early postoperative factors that could predict long-term endocrinological remission.METHODSThe clinical, radiological, and pathological characteristics and surgical and endocrinological outcomes of 31 consecutive cases of TSHomas that were surgically treated between 2005 and 2017 were reviewed retrospectively. Preoperative factors were evaluated for their ability to predict long-term remission by comparing remission and nonremission groups. TSH and free thyroxine levels were measured at 2, 6, 12, 18, and 24 hours after surgery to determine whether they could predict long-term remission.RESULTSGross-total removal of tumor was achieved in 28 patients (90.3%), and 26 patients (83.9%) achieved endocrinological remission by surgery alone based on long-term endocrinological follow-up (median 50 months, range 32–81 months). The majority of the tumors were solid (21/31, 67.7%), and en bloc resection was possible in 16 patients (51.6%). Larger tumor size and tumor invasion into cavernous sinus and sphenoid sinus were strong predictors of lower rates of endocrinological remission. Immediate postoperative TSH level at 12 hours after surgery was the strongest predictor, with a 0.62 μIU/mL cutoff. Postoperative complications included CSF rhinorrhea in one patient and epistaxis in another patient, who underwent additional surgical treatment for the complications.CONCLUSIONSTumor size and extent are major prognostic factors for both extent of resection and endocrinological remission. The consistency of TSHomas was more likely to be solid, which makes extracapsular dissection more feasible. Long-term remission of TSHomas could be predicted even during the early postoperative period.

Thyroid Stimulating Hormone Measurement by an Ultrasensitive Assay during Thyroxine Replacement: Comparison with other Tests of Thyroid Function

1987 ◽  
Vol 24 (6) ◽  
pp. 614-619 ◽  
Author(s):  
T Wheatley ◽  
P M S Clark ◽  
J D A Clark ◽  
P R Raggatt ◽  
O M Edwards
Keyword(s):  
Replacement Therapy ◽  
Thyroid Function ◽  
Thyroid Stimulating Hormone ◽  
Biochemical Tests ◽  
Basal Serum ◽  
Total Thyroxine ◽  
Thyroxine Replacement ◽  
Thyroxine Replacement Therapy ◽  
Serum Tsh ◽  
Stimulating Hormone

Serum thyroid stimulating hormone (TSH) was measured using a highly sensitive enzyme-amplified immunoassay in 37 clinically euthyroid patients receiving thyroxine replacement therapy and compared with other biochemical tests of thyroid function. A highly significant correlation ( P<0·001) was found between the basal serum TSH and the increase in serum TSH concentration 20 min after the administration of thyrotropin releasing hormone (TRH). The basal serum TSH was negatively correlated with the serum total thyroxine ( P=0·05). When patients results were classified as abnormal or normal many discrepancies were noted between the various thyroid tests. A suppressed serum TSH was found in 65% of patients with a normal serum total thyroxine. However, in patients on thyroxine replacement therapy a basal TSH measured by enzyme-amplified immunoassay provides the same information as a TRH test.

scholarly journals The Effect of Thyroid-Stimulating Hormone on Tumor Size in Differentiated Thyroid Carcinoma

2014 ◽  
Vol 77 (S3) ◽  
pp. 967-970 ◽  
Author(s):  
I. A. Ozemir ◽  
B. Gurbuz ◽  
B. Bayraktar ◽  
S. Aslan ◽  
A. Başkent ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Tumor Size ◽  
Differentiated Thyroid Carcinoma ◽  
Thyroid Stimulating Hormone ◽  
Stimulating Hormone

scholarly journals Double variants in TSHR and DUOX2 in a patient with hypothyroidism: case report

2019 ◽  
Vol 32 (11) ◽  
pp. 1299-1303 ◽  
Author(s):  
Zerin Sasivari ◽  
Gabor Szinnai ◽  
Britta Seebauer ◽  
Daniel Konrad ◽  
Mariarosaria Lang-Muritano
Keyword(s):  
Elevated Serum ◽  
Thyroid Stimulating Hormone ◽  
Phenotype Correlation ◽  
Pathogenic Variants ◽  
Dual Oxidase ◽  
Thyroid Dyshormonogenesis ◽  
Thyroxine Replacement ◽  
Double Heterozygosity ◽  
Tsh Levels ◽  
Stimulating Hormone

Abstract Thyroid dyshormonogenesis (TDH) is characterized by the defective synthesis of thyroid hormones. We present a patient with congenital hypothyroidism (CH) who presented in newborn screening with elevated serum thyroid-stimulating hormone (TSH), decreased free thyroxine (fT4) and increased thyroglobulin (Tg) concentrations. Ultrasound scan revealed a properly structured thyroid gland. Treatment with L-thyroxine was initiated. At the age of 2 years, thyroxine replacement was stopped. The patient remained untreated until 6 years of age when TSH levels progressively increased and L-thyroxine treatment was restarted at a dose of 12.5 μg/day. Genetic analysis revealed a double heterozygosity for likely pathogenic variants of dual oxidase 2 (DUOX2) and thyroid stimulating hormone receptor (TSHR). Both genes were earlier shown to be associated with CH. In a literature review, our patient was compared to previously published patients with similar clinical characteristics, and a good genotype-phenotype correlation was identified.

CLINICAL EVALUATION OF THE THYROID STIMULATING HORMONE ACTIVITY IN EXOPHTHALMOS

1961 ◽  
Vol 38 (4) ◽  
pp. 577-584 ◽  
Author(s):  
Sven Erik Björkman ◽  
Torsten Denneberg ◽  
Inge Hedenskog
Keyword(s):  
Clinical Evaluation ◽  
Thyroid Stimulating Hormone ◽  
Significant Rise ◽  
Hormone Activity ◽  
Control Subjects ◽  
Long Duration ◽  
Stimulating Factor ◽  
Stimulating Hormone

ABSTRACT A method for demonstrating the presence of a thyroid stimulating factor in the blood of patients with progressive exophthalmos after thyroidectomy or after treatment with radioiodine is described. The method consists of transfusing freshly drawn blood from the patients to euthyroid recipients and subsequently following the PBI level of the recipients at regular intervals. Six exophthalmic patients tested in this manner were found to have such a factor in their circulating blood. After transfusion of their blood a significant rise in the PBI level of the recipients could be demonstrated. Two other patients, one with exophthalmos of long duration did not show this response nor did it occur after transfusion of blood from two control subjects. In one case the action of this factor was compared with that of animal thyrotrophin and found to be of the same magnitude.

Sign in / Sign up

Export Citation Format

Share Document